Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Free Report

White Paper_2017_State of China Life Science

State of China Life Science - 2017H1

Over $10B invested in last 18 months! Download free report on life science investment in China.

Ascletis Raises $100 Million for US-China Startup

publication date: Apr 6, 2011
View a Printer Friendly version of this page, allowing you to print the page.
Ascletis, Inc., a US-China biopharma startup, announced a huge $100 million Series A round, led by Hangzhou Binjiang Investment Holding Co. Initially, Ascletis will in-license promising clinical-stage western molecules for cancer and infectious diseases, which it will take to China for development and sale there. To lock down a financial commitment of this size, Ascletis probably has its eyes on some compelling projects, but the company isn’t talking about its prospects before a deal is signed. To get its business moving quickly – the company hopes to have a drug on the market in three to five years – Ascletis is focusing on projects that are already in clinical stage in the west. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China